J&J pays $785M upfront to partner with Flagship's Sail Biomedicines on in vivo CAR-T for autoimmune diseases, with option to acquire Sail for $2.58B more.
The in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role.
Johnson & Johnson is paying …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might…
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly…
